Search tips
Search criteria 


Logo of jbcThe Journal of Biological Chemistry
J Biol Chem. 2010 June 18; 285(25): 19402–19408.
Published online 2010 April 27. doi:  10.1074/jbc.M110.120774
PMCID: PMC2885220

Repair of Isoaspartate Formation Modulates the Interaction of Deamidated 4E-BP2 with mTORC1 in Brain*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg


In eukaryotes, a rate-limiting step of translation initiation is recognition of the mRNA 5′ m7GpppN cap structure by the eukaryotic initiation factor 4F (eIF4F), a heterotrimeric complex consisting of the cap-binding protein, eIF4E, along with eIF4G, and eIF4A. The eIF4E-binding proteins (4E-BPs) repress translation by disrupting eIF4F formation, thereby preventing ribosome recruitment to the mRNA. Of the three 4E-BPs, 4E-BP2 is the predominant paralog expressed in the mammalian brain and plays an important role in synaptic plasticity and learning and memory. 4E-BP2 undergoes asparagine deamidation, solely in the brain, during early postnatal development. Deamidation spontaneously converts asparagines into a mixture of aspartates or isoaspartates, the latter of which may be destabilizing to proteins. The enzyme protein l-isoaspartyl methyltransferase (PIMT) prevents isoaspartate accumulation by catalyzing the conversion of isoaspartates to aspartates. PIMT exhibits high activity in the brain, relative to other tissues. We report here that 4E-BP2 is a substrate for PIMT. In vitro deamidated 4E-BP2 accrues isoapartyl residues and is methylated by recombinant PIMT. Using an antibody that recognizes 4E-BP2, which harbors isoaspartates at the deamidation sites, Asn99 and Asn102, we demonstrate that 4E-BP2 in PIMT−/− brain lysates contains isoaspartate residues. Further, we show that 4E-BP2 containing isoaspartates lacks the augmented association with raptor that is a feature of deamidated 4E-BP2.

Keywords: Brain, mTOR Complex (mTORC), Protein Methylation, S-Adenosylmethionine (SAM), Translation, 4E-BP2, Deamidation, Isoaspartate, Protein l-Isoaspartyl Methyltransferase (PIMT)


Eukaryotic mRNA translation is regulated primarily at the initiation phase, during which the ribosome is recruited to the mRNA. The association of the cap-binding protein, eukaryotic initiation factor (eIF)5 4E, with the mRNA 5′ m7GpppN cap structure, initiates an ordered series of reactions culminating in 40 S ribosome placement at the AUG (or its cognate) initiation codon. eIF4E binds the mRNA cap as part of a complex, termed eIF4F, which includes the initiation factors eIF4G and eIF4A. eIF4F recruits the ribosomal 43 S complex (40 S ribosome/Met-tRNA1Met-eIF2-GTP/eIF3) to the mRNA 5′ untranslated region (1,3). In mammals, three eIF4E-binding proteins (4E-BPs) (4) impair translation initiation by preventing eIF4F formation through competition with eIF4G for a common binding site on eIF4E (5,7). Under conditions favoring growth and proliferation, the 4E-BPs are hyperphosphorylated by the mammalian target of rapamycin complex 1 (mTORC1), which causes their release from eIF4E, eIF4F formation, and promotion of translation initiation (8,10).

mTORC1 is composed of the kinase mTOR, G protein β-subunit-like protein, and regulatory associated protein of mTOR (raptor), a large adaptor protein that recruits substrates to the mTOR kinase domain (11,14). A TOR signaling (TOS) motif common to mTORC1 substrates, including 4E-BPs, is necessary for the interaction with raptor (15,18). mTORC1 kinase activity is regulated by several signaling pathways, including phosphoinositide 3-kinase-protein kinase B, and serine/threonine kinase 11-AMP-activated protein kinase, which converge on the tuberous sclerosis complex to suppress its GTPase activity toward the small GTP-binding protein ras homolog enriched in brain, an activator of mTORC1 (19, 20).

Asparagine deamidation is a posttranslational protein modification comprising the nonenzymatic conversion of asparagines to aspartates. Although this process is spontaneous, the propensity of asparagines to undergo deamidation is dramatically disparate and is largely determined by the identity of the immediate C-terminal residue and the flexibility of the peptide backbone (21,23). Environmental factors, including pH, temperature, and ion concentration, also significantly influence deamidation rates (24). In vivo deamidation has been reported for >200 proteins (25). Although this modification has often been viewed as undesirable degradation of aged proteins, important molecular and cellular functions of deamidated B cell lymphoma-xL, fibronectin, histone H1o, cytochrome c, protein kinase A, and rabbit muscle aldolase have been described (25, 26). The apparent evolutionary selection of sequences favoring asparagine deamidation (27, 28) and the coincidence of in vivo deamidation events with cellular processes suggest that deamidation may act as a “molecular clock ” to regulate the onset of biologically significant events (28, 29). Indeed, protein deamidation may regulate diverse cellular processes, which include protein turnover (28, 30, 31), apoptosis (32, 33), chromatin remodeling (34), and regulation of cellular-matrix interactions (35).

Deamidation occurs through nucleophilic attack by the C-terminal flanking peptide bond nitrogen toward an asparagine side chain amide group. This leads to the formation of a circular succinimide intermediate (36) (Fig. 1A). The hydrolysis of this short lived intermediate (physiological half-life of a few hours) yields both aspartate and isoaspartate residues, the latter of which comprise 70–85% of the reaction product (37). The atypical peptide bond (β-linkage) of the isoaspartyl residue prevents proper protein folding and is therefore thought to represent a form of damage to proteins aged in vitro or that accumulate in some tissues (36, 38, 39). To alleviate the potentially deleterious consequences of isoaspartate accumulation, the enzyme protein l-isoaspartyl methyltransferase (PIMT) promotes the conversion of these residues into the aspartate form. This occurs through the PIMT-catalyzed transfer of a methyl group from S-adenosyl-l-methionine (AdoMet) to the isoaspartyl carboxyl side-chain leading to reformation of the succinimide group (40, 41) (Fig. 1A). Iterative PIMT-catalyzed succinimide formation and decay thereby leads to replacement of isoaspartates with aspartates (42,44). PIMT is ubiquitous, although it exhibits high expression and has the greatest number of substrates in brain (45, 46). The critical requirement for this enzyme in neuronal function is underscored by its genetic deletion in mice. Most strikingly, of a host of reported maladies, PIMT−/− mice display enlarged brains, suffer severe epileptic seizures, and die on average 6 weeks postnatally (45, 47). Transgenic flies overexpressing PIMT exhibit increased lifespan (48), possibly through suppression of isoaspartate content. Because of the importance of PIMT in the brain, two recent studies were independently undertaken to globally identify its substrates in this tissue (46, 49). The considerable discrepancy in the identified PIMT substrates from these reports suggests that still other targets of this enzyme remain unidentified.

PIMT repairs isoaspartates formed during spontaneous asparagine deamidation in proteins. A, mechanism of aspartate or isoaspartate formation and repair of abnormal isoaspartyls by PIMT. Spontaneous asparagine deamidation yields a mix of aspartyls and ...

We recently discovered that the translation repressor 4E-BP2, the predominant 4E-BP paralog expressed in the mammalian brain, undergoes brain-specific deamidation during postnatal development at a unique asparagine-rich sequence (50). Considering this, we investigated whether 4E-BP2 is a PIMT substrate.



AdoMet (81.9 Ci/mmol) and unlabeled AdoMet were purchased from PerkinElmer Life Sciences and Sigma, respectively. EN3HANCETM liquid autoradiography enhancer was from PerkinElmer Life Sciences. 4E-BP2 (no. 2845) antibody was from Cell Signaling Technology, and raptor antibody was from Millipore.

Vector Construction and Recombinant Protein Expression and Purification

Human PIMT cDNA was amplified by PCR with the addition of EcoRI and XhoI restriction sites at the 5′ and 3′ ends, respectively. The PCR product was digested and ligated into the pGEX-6P-1 vector at the above sites in-frame with the upstream glutathione S-transferase (GST) sequence. Recombinant GST-PIMT fusion protein was expressed in Escherichia coli BL21 (DE3) by induction with 0.1 mm isopropyl 1-thio-β-d-galactopyranoside, followed by 3-h growth at 30 °C. Protein was purified on glutathione-Sepharose 4B resin according to the manufacturer's recommendations (GE Healthcare) and eluted in fractions with 10 mm glutathione in 50 mm Tris-HCl, pH 8.5. In the case of recombinant GST-4E-BP2 fusion proteins, the 4E-BP moieties were released, following binding to glutathione-Sepharose 4B, by on-resin cleavage for 20 h at 4 °C with PreScission Protease (GE Healthcare). All purified proteins were stored at −80 °C in 10% glycerol.

In Vitro Methylation of Isoaspartates by Recombinant PIMT

Methylation of brain lysates was performed as described previously (49). Briefly, 40 μg of lysate was incubated with 2.5 μm GST-PIMT, 100 μm AdoMet (4 μCi of 3H-labeled; concentration and specific activity were adjusted with unlabeled AdoMet), and 75 mm Na-MES, pH 6.2, in a total reaction volume of 27.5 μl. For methylation of recombinant 4E-BP2, the wild type protein was in vitro deamidated in 0.15 m Tris-HCl, pH 10, for 24 h at 37 °C. The protein solution was then neutralized with 0.5 m Na-MES and treated with 1 mm dithiothreitol for 10 min. Control wild type and 4E-BP2 N99D/N102D recombinant proteins were similarly treated with 0.5 m Na-MES and 1 mm dithiothreitol immediately before use. Methylation reactions were then carried out in 25-μl volumes containing 1 μg of recombinant protein, 2.5 μm GST-PIMT, 50 μm AdoMet (4 μCi), and 75 mm Na-MES (pH 6.2). In both cases, reactions were for 15 min at 30 °C and stopped by the addition of 5 × Laemmli sample buffer. Samples were resolved on 4–12% Criterion XT BisTris gels, pH 6.4 (Bio-Rad). Gels were then treated with EN3HANCETM, dried, and exposed to autoradiographic film for tritium detection.

Raptor Immunoprecipitation and in Vitro Binding Assays

Raptor antibody was absorbed onto protein G-Sepharose beads for 30 min in homogenization buffer (10 mm K3PO4/1 mm EDTA, 10 mm MgCl2, 50 mm β-glycerophosphate, 5 mm EGTA, 0.5% Nonidet P-40, 0.1% Brij 35, 0.1% sodium deoxycholate, 1 mm sodium orthovanadate, 1 mm phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin). Brain lysate from 4E-BP2−/− mice was prepared in homogenization buffer, clarified by centrifugation, and 500 μg was incubated with 10 μl of prepared beads for 30 min to immunoprecipitate raptor. The indicated recombinant 4E-BP2 proteins (150 ng) were then mixed with immune complexes and incubated for 2 h at 4 °C with agitation. Beads were washed four times with 500 μl of homogenization buffer, resuspended in sample buffer, and subjected to SDS-PAGE (5–20%).

SDS-PAGE and Western Blotting

Protein samples were resolved by SDS-PAGE (15%) and electroblotted onto nitrocellulose membranes. Membranes were blocked in 5% powdered milk in Tris-buffered saline with 0.1% Tween 20 (TBST) for 1 h followed by incubation with primary antibodies for 2 h at room temperature or overnight at 4 °C. Membranes were then washed with TBST three times and incubated with horseradish peroxidase-coupled secondary antibody for 1 h at room temperature, washed again, and treated with enhanced chemiluminescence prior to detection on x-ray film (Denville Scientific).

Iso4E-BP2 (Asp99/Asp102) Antibody Production and Purification

A peptide of amino acid sequence identical to that encompassing the deamidation susceptible region of 4E-BP2, with aspartates in β-linkages (isoaspartates) replacing asparagines 99 and 102, was purchased from American Peptide. The peptide was conjugated to immunogenic keyhole limpet hemocyanin via an ectopic N-terminal cysteine using the Imject Maleimide Conjugation kit (Pierce). Rabbits were immunized with the conjugated peptide, using Freund's Complete Adjuvant for first injection and Freund's Incomplete Adjuvant for subsequent injections, according to the McGill Animal Resources Centre protocol. For antibody purification, rabbit serum was incubated with the above peptide that had been previously conjugated to resin using the SulfoLink kit (Pierce). The antibody was eluted at low pH, dialyzed against 50% glycerol, and stored at −20 °C.


GST-PIMT Exhibits Functional Methyltransferase Activity in Vitro

Two 4E-BP2 asparagine residues (Asn99 and Asn102; Fig. 1B) are deamidated during postnatal development in the mammalian brain (50). Considering the preponderance for isoaspartate accumulation and the critical requirement for PIMT in the brain (45, 47), we hypothesized that 4E-BP2 would be a PIMT substrate. To address this, we first adopted an in vitro assay system based on the use of recombinant PIMT, similar to that used in previous studies (46, 49, 51). To produce recombinant PIMT, the human PIMT isozyme II cDNA was subcloned into the pGEX-6P-1 vector for bacterial expression as a fusion protein to GST at the PIMT N terminus. Recombinant GST-PIMT was expressed in E. coli BL21 cells and purified to homogeneity (Fig. 2A). The activity of GST-PIMT was assessed by incubating it with wild type or PIMT−/− brain lysates and the tritiated methyl donor, AdoMet. As anticipated, GST-PIMT efficiently labeled the isoaspartates that accumulate in PIMT−/− brains, relative to wild type, as was evidenced by the pronounced tritium signals across the entire molecular weight range of the PIMT−/− PAGE lane (Fig. 2B). Similar results were previously obtained with different preparations of recombinant PIMT protein (46, 49).

Purified GST-tagged PIMT exhibits methyltransferase activity toward isoaspartyl residues in PIMT−/− brain lysates. A, expression and purification of N-terminal GST-tagged PIMT is depicted. Human PIMT was expressed in E. coli as a fusion ...

In Vitro Deamidated 4E-BP2 Accrues Isoaspartates

To determine whether 4E-BP2 deamidation produces isoaspartates, in addition to aspartyl residues, the PIMT assay was adapted for methylation of in vitro deamidated 4E-BP2. Recombinant 4E-BP2 was subjected to alkaline-induced deamidation, pH 10, by incubation for 24 h at 37 °C. This treatment produced similar quantities of unmodified, singly, and doubly deamidated 4E-BP2 (Fig. 3, upper panel, middle lane). PIMT methylation was then performed on alkaline-treated 4E-BP2, untreated wild type 4E-BP2, and the deamidation mimic 4E-BP2 N99D/N102D (described in Ref. 50). As expected, isoaspartyl groups were only detected in the wild type 4E-BP2 protein that was deamidated by alkaline treatment (wt; pH 10) (Fig. 3, lower panel). Thus, the formation of isoaspartyl residues during in vitro asparagine deamidation of 4E-BP2 renders it a PIMT substrate. Importantly, recombinant PIMT distinguishes between the isoaspartates of alkaline-treated 4E-BP2 and the aspartates at the same residues in 4E-BP2 N99D/N102D.

In vitro deamidated 4E-BP2 accrues isoaspartyl residues and is a substrate for PIMT. Recombinant 4E-BP2 was alkaline-deamidated in 0.15 m Tris-HCl, pH 10, for 24 h at 37 °C. Wild type (wt), alkaline-treated (wt+pH10), and the deamidated mimic ...

Antibody Specifically Recognizes 4E-BP2 Containing Isoaspartyls at Positions 99 and 102

To characterize further the isoaspartate formation in 4E-BP2, an antibody was produced that recognizes 4E-BP2 harboring isoaspartyl residues at both positions 99 and 102. The specificity of the immunopurified antibody was confirmed by Western blotting against recombinant 4E-BP2 proteins. The antibody, herein referred to as anti-iso4E-BP2 (Asp99/Asp102), predominantly recognized 4E-BP2 that had been deamidated by alkaline treatment (Fig. 4A), thereby confirming its specificity for 4E-BP2 containing isoaspartates at these two positions. Very faint cross-reactivity was noticed with the nonisoaspartate 4E-BP2 N99D/N102D variant. This antibody also weakly detects 4E-BP2 containing a single isoaspartate at position 102, particularly when position 99 is concomitantly occupied by an aspartate, as shown in supplemental Fig. 1. Increasing amounts of isoaspartates were also detected with this antibody in recombinant wild type 4E-BP2 that had been “aged ” in vitro by incubation for several days at pH 7 (Fig. 4B).

Antibody raised in-house specifically recognizes 4E-BP2 harboring isoaspartyl residues at positions 99 and 102. A, Western blot analysis using IgG purified from rabbit serum that was raised against a peptide containing the 4E-BP2 residues 99 and 102 in ...

4E-BP2 Is an in Vivo PIMT Substrate in Brain

Our previous work demonstrated that 4E-BP2 undergoes deamidation, uniquely in the brain, during the first 3 murine postnatal weeks (50). Thus, anti-iso4E-BP2 (Asp99/Asp102) antibody was used to determine whether 4E-BP2, the predominant 4E-BP expressed in the mammalian brain, is an in vivo substrate for PIMT in this organ. 4E-BP2 was immunoprecipitated from wild type or PIMT−/− brains lysates using anti-4E-BP2 antibody, and proteins were resolved by SDS-PAGE. Immunoprecipitation from 4E-BP2−/− brain lysates served as a negative control for antibody specificity. Western blotting with anti-iso4E-BP2 (Asp99/Asp102) antibody indicated that only 4E-BP2 from PIMT−/− brains contained appreciable amounts of isoaspartyl residues (Fig. 5). Faint signals in the wild type lane are likely due to cross-reactivity with unrelated proteins accumulated during the immunoprecipitation procedure, rather than with 4E-BP2 itself, as similar signals are also present in the 4E-BP2−/− lane.

4E-BP2 is an in vivo substrate for PIMT in the mammalian brain. Western blot analysis using the iso4E-BP2 D99/D102 antibody (Fig. 4) detects isoaspartyl residues in 4E-BP2 from PIMT−/− brain lysates. 4E-BP2 was immnoprecipitated from 200 ...

Isoaspartate Accumulation in 4E-BP2 Does Not Alter Its Stability but Renders It Defective for Enhanced Raptor Binding

Formation of isoaspartyl residues in some proteins has been associated with either increased proteasomal degradation (52, 53) or aggregation (54). We therefore asked whether the accumulation of isoaspartates in 4E-BP2 in the PIMT−/− brain affects the stability of the protein. Western blotting on wild type and PIMT−/− brain lysates from animals aged approximately between 6 and 14 weeks postnatally indicated no apparent change in steady-state levels of 4E-BP2, thereby suggesting that 4E-BP2 is not subject to aberrant degradation or aggregation in the absence of PIMT-mediated repair (Fig. 6A). We previously reported that deamidation of 4E-BP2 enhances its interaction with raptor (50). Thus, we questioned whether deamidated 4E-BP2 containing primarily isoaspartates at the deamidation sites maintained increased raptor association. To address this, recombinant 4E-BP2 was treated at high pH to induce deamidation and then assayed for in vitro association with raptor protein, which had been previously immunoprecipitated from cell lysates and immobilized on protein G-Sepharose resin. It is noteworthy that the longer pH 10 treatments performed here on recombinant 4E-BP2 proteins (72 h) yielded a single isoapartyl-containing isoform derived from wild type protein (doubly deamidated) as opposed to the three forms found following a shorter treatment (Figs. 3 and and44A). This uniformity allows ease of comparison in raptor binding relative to the other 4E-BP2 variants. In agreement with our earlier findings (50), the deamidation mimic, 4E-BP2 N99D/N102D, exhibited a dramatic enhancement in raptor binding, relative to the wild type form (Fig. 6B, compare second and third lanes). Strikingly, in vitro deamidated 4E-BP2 (4E-BP2; pH 10) which contains isoaspartates at the principal deamidation sites displayed raptor binding efficiency similar to that of wild type 4E-BP2 and thus was considerably reduced with respect to the deamidation mimic (Fig. 6B, compare fourth lane with second and third lanes). No binding was detected for 4E-BP2 variants lacking the C-terminal residues comprising the TOS motif, which is required for interaction with raptor, as we demonstrated previously (50). Thus, this result indicates that the accumulation of isoaspartates in 4E-BP2 during deamidation counteracts its gain of function in raptor-binding.

Accumulation of isoaspartyl residues in 4E-BP2 in the brain does not alter protein stability but reduces its interaction with raptor relative to 4E-BP2 N99D/N102D. A, steady-state level of 4E-BP2 is unaffected in PIMT−/− brains as assessed ...


We report here that 4E-BP2 is a substrate of PIMT. Deamidation of endogenous 4E-BP2 in the PIMT−/− murine brain or of recombinant 4E-BP2 deamidated under alkaline pH or by in vitro aging caused the formation of isoaspartyl residues. Detection of isoaspartates in 4E-BP2 in the PIMT−/− brain indicates that 4E-BP2 is an accessible intracellular substrate to PIMT and that PIMT normally acts to suppress isoaspartate accumulation following deamidation in the wild type brain. 4E-BP2 deamidation occurs principally on two asparagines (Asn99 and Asn102) near the C terminus (50), and this leads to slower migration of the deamidated species in SDS-PAGE. Thus, in the PIMT−/− brain the slow migrating forms of 4E-BP2 harbor 70–85% isoaspartyl content at each deamidation site, as this is the ratio favored by succinimide hydrolysis. Our antibody directed against 4E-BP2, containing isoaspartates at the deamidation sites (anti-iso4E-BP2), recognized the slowest migrating 4E-BP2 species formed by alkaline-induced deamidation (Fig. 4). In using this antibody to demonstrate, by Western blotting, the accumulation of isoaspartyls in 4E-BP2 from PIMT−/− brain lysates (Fig. 5), it was also shown that the 4E-BP2 signal from wild type brain was not above background levels (determined with the 4E-BP2−/− lysate). This indicates that PIMT-mediated repair of 4E-BP2 is sufficiently efficacious to maintain it in the aspartate-containing form, at least as given by the limit of detection of this assay.

The appearance and accumulation of 4E-BP2 deamidation in murine brain in the early postnatal weeks parallel approximately those of PIMT expression (50, 55). This suggests that, in addition to 4E-BP2, numerous PIMT substrates accrue isoaspartyl residues during the same time frame and that increased PIMT expression is required to catalyze the conversion to aspartates sufficiently. Indeed, the large number of isoaspartates formed in the brain, relative to other tissues, rapidly increases within the first 100 postnatal days in PIMT−/− mice (56).

Studies aimed at cataloguing the complement of PIMT substrates in the brain did not identify 4E-BP2 as a substrate (46, 49). A possible explanation for this is that 4E-BP2 from the PIMT−/− brain lysates yielded either a minor radiolabel signal from exogenous PIMT methylation or was not detected by protein staining in the two-dimensional isoelectric focusing SDS-PAGE analyses. Consequently, it would not have been identified.

Isoaspartyl groups tend to preclude several different protease activities (52, 57, 58). In contrast, other work suggests that isoaspartates predispose calmodulin to elevated rates of ubiquitin-independent proteasomal degradation (53). Similarly, total isoaspartate levels are maintained at a constant level in aged PIMT-deficient mice (greater than 100 days of age) by enhanced degradation and urinary excretion of damaged proteins (56). Thus, it is conceivable that isoasparate accumulation in 4E-BP2 in PIMT−/− mice might affect the stability or turnover of the protein. However, no changes were observed in 4E-BP2 levels upon comparing wild type and PIMT−/− brain lysates from mice aged between 40 and 100 days (Fig. 6A). Although no gross changes in 4E-BP2 expression arise from isoaspartate formation in PIMT−/− brains in the first 100 postnatal days, it is possible that 4E-BP2 harboring isoaspartyl residues would be degraded and excreted in older knock-out mice in which total brain isoaspartyl content has reached a plateau. We observed that 4E-BP2 deamidated in vitro, so as to accrue isoaspartates at positions 99 and 102, lost the proclivity for enhanced raptor association that is a function exhibited by deamidated 4E-BP2 (not harboring isoaspartyls), relative to the wild type protein (Fig. 6B). 4E-BP2 deamidation occurs in the brain during early postnatal development (50). Therefore, the PIMT-catalyzed methylation of 4E-BP2 to prevent isoaspartate accumulation may be necessary to preserve the enhanced association of deamidated 4E-BP2 with raptor in the nervous system.

Genetic ablation of 4E-BP2 in mice begets impairments in certain forms of learning and memory and alters synaptic plasticity, a cellular correlate of memory formation (59,61). Moreover, 4E-BP2 undergoes deamidation during early postnatal development, and expression of deamidated 4E-BP2 in hippocampal CA1 neurons slows the kinetics of excitatory synaptic transmission at the Schaffer collateral pathway (50). Considering this, it is conceivable that PIMT-mediated suppression of isoaspartate accumulation in deamidated 4E-BP2 in brain may be required for optimal synaptic function during memory formation. In summary, we have identified 4E-BP2 as an endogenous substrate for PIMT-mediated repair of isoaspartyl residues that accrue by asparagine deamidation in postnatal brain development.

Supplementary Material

Supplemental Data:


We thank Jon Lowenson and Steven Clarke for the human PIMT cDNA and PIMT−/− brains and for helpful discussions and critical reading of the manuscript. We thank Colin Lister and Annie Sylvestre for excellent technical assistance.

*This work was supported by a Canadian Institutes of Health Research (CIHR) Team grant and a Howard Hughes Medical Institute grant (to N. S.).

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThe on-line version of this article (available at contains supplemental Fig. 1.

5The abbreviations used are:

eukaryotic initiation factor
eIF4E-binding protein
mammalian target of rapamycin complex 1
regulatory associated protein of mTOR
TOR signaling
protein l-isoaspartyl methyltransferase
glutathione S-transferase
4-morpholineethanesulfonic acid


1. Gingras A. C., Raught B., Sonenberg N. (1999) Annu. Rev. Biochem. 68, 913–963 [PubMed]
2. Sonenberg N., Hinnebusch A. G. (2009) Cell 136, 731–745 [PMC free article] [PubMed]
3. Pestova T. V., Lorsch J. R., Hellen C. U. T. (2007) in Translational Control in Biology and Medicine (Mathews M. B., Sonenberg N., Hershey J. W. B., editors. , eds) pp. 87–128, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
4. Gingras A. C., Svitkin Y., Belsham G. J., Pause A., Sonenberg N. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 5578–5583 [PubMed]
5. Marcotrigiano J., Gingras A. C., Sonenberg N., Burley S. K. (1999) Mol. Cell 3, 707–716 [PubMed]
6. Mader S., Lee H., Pause A., Sonenberg N. (1995) Mol. Cell. Biol. 15, 4990–4997 [PMC free article] [PubMed]
7. Haghighat A., Mader S., Pause A., Sonenberg N. (1995) EMBO J. 14, 5701–5709 [PubMed]
8. Gingras A. C., Raught B., Sonenberg N. (2001) Genes Dev. 15, 807–826 [PubMed]
9. Proud C. G. (2009) Biochem. Soc. Trans. 37, 227–231 [PubMed]
10. Yonezawa K., Yoshino K. I., Tokunaga C., Hara K. (2004) Curr. Top. Microbiol. Immunol. 279, 271–282 [PubMed]
11. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J. L., Bonenfant D., Oppliger W., Jenoe P., Hall M. N. (2002) Mol. Cell 10, 457–468 [PubMed]
12. Kim D. H., Sarbassov D. D., Ali S. M., King J. E., Latek R. R., Erdjument-Bromage H., Tempst P., Sabatini D. M. (2002) Cell 110, 163–175 [PubMed]
13. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. (2002) Cell 110, 177–189 [PubMed]
14. Kim D. H., Sarbassov D. D., Ali S. M., Latek R. R., Guntur K. V., Erdjument-Bromage H., Tempst P., Sabatini D. M. (2003) Mol. Cell 11, 895–904 [PubMed]
15. Lee V. H., Healy T., Fonseca B. D., Hayashi A., Proud C. G. (2008) FEBS J. 275, 2185–2199 [PubMed]
16. Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K., Hara K., Tanaka N., Avruch J., Yonezawa K. (2003) J. Biol. Chem. 278, 15461–15464 [PubMed]
17. Schalm S. S., Blenis J. (2002) Curr. Biol. 12, 632–639 [PubMed]
18. Schalm S. S., Fingar D. C., Sabatini D. M., Blenis J. (2003) Curr. Biol. 13, 797–806 [PubMed]
19. Ma X. M., Blenis J. (2009) Nat. Rev. Mol. Cell Biol. 10, 307–318 [PubMed]
20. Wullschleger S., Loewith R., Hall M. N. (2006) Cell 124, 471–484 [PubMed]
21. Robinson N. E., Robinson A. B. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 12409–12413 [PubMed]
22. Xie M., Schowen R. L. (1999) J. Pharm. Sci. 88, 8–13 [PubMed]
23. Radkiewicz J. L., Zipse H., Clarke S., Houk K. N. (2001) J. Am. Chem. Soc. 123, 3499–3506 [PubMed]
24. Patel K., Borchardt R. T. (1990) Pharm. Res. 7, 703–711 [PubMed]
25. Weintraub S. J., Deverman B. E. (2007) Sci. STKE 2007, re7. [PubMed]
26. Pepperkok R., Hotz-Wagenblatt A., König N., Girod A., Bossemeyer D., Kinzel V. (2000) J. Cell Biol. 148, 715–726 [PMC free article] [PubMed]
27. Robinson A. B., Robinson L. R. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 8880–8884 [PubMed]
28. Robinson A. B., McKerrow J. H., Cary P. (1970) Proc. Natl. Acad. Sci. U.S.A. 66, 753–757 [PubMed]
29. Robinson N. E., Robinson A. B. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 944–949 [PubMed]
30. Flatmark T. (1967) J. Biol. Chem. 242, 2454–2459 [PubMed]
31. Midelfort C. F., Mehler A. H. (1972) Proc. Natl. Acad. Sci. U.S.A. 69, 1816–1819 [PubMed]
32. Deverman B. E., Cook B. L., Manson S. R., Niederhoff R. A., Langer E. M., Rosová I., Kulans L. A., Fu X., Weinberg J. S., Heinecke J. W., Roth K. A., Weintraub S. J. (2002) Cell 111, 51–62 [PubMed]
33. Zhao R., Oxley D., Smith T. S., Follows G. A., Green A. R., Alexander D. R. (2007) PLoS Biol. 5, e1. [PubMed]
34. Lindner H., Sarg B., Grunicke H., Helliger W. (1999) J. Cancer Res. Clin. Oncol. 125, 182–186 [PubMed]
35. Curnis F., Longhi R., Crippa L., Cattaneo A., Dondossola E., Bachi A., Corti A. (2006) J. Biol. Chem. 281, 36466–36476 [PubMed]
36. Reissner K. J., Aswad D. W. (2003) Cell Mol. Life Sci. 60, 1281–1295 [PubMed]
37. Geiger T., Clarke S. (1987) J. Biol. Chem. 262, 785–794 [PubMed]
38. Shimizu T., Matsuoka Y., Shirasawa T. (2005) Biol. Pharm. Bull. 28, 1590–1596 [PubMed]
39. Clarke S. (2003) Ageing Res. Rev. 2, 263–285 [PubMed]
40. Aswad D. W. (1984) J. Biol. Chem. 259, 10714–10721 [PubMed]
41. Murray E. D., Jr., Clarke S. (1984) J. Biol. Chem. 259, 10722–10732 [PubMed]
42. Johnson B. A., Murray E. D., Jr., Clarke S., Glass D. B., Aswad D. W. (1987) J. Biol. Chem. 262, 5622–5629 [PubMed]
43. McFadden P. N., Clarke S. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 2595–2599 [PubMed]
44. Brennan T. V., Anderson J. W., Jia Z., Waygood E. B., Clarke S. (1994) J. Biol. Chem. 269, 24586–24595 [PubMed]
45. Kim E., Lowenson J. D., MacLaren D. C., Clarke S., Young S. G. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 6132–6137 [PubMed]
46. Vigneswara V., Lowenson J. D., Powell C. D., Thakur M., Bailey K., Clarke S., Ray D. E., Carter W. G. (2006) J. Biol. Chem. 281, 32619–32629 [PubMed]
47. Yamamoto A., Takagi H., Kitamura D., Tatsuoka H., Nakano H., Kawano H., Kuroyanagi H., Yahagi Y., Kobayashi S., Koizumi K., Sakai T., Saito K., Chiba T., Kawamura K., Suzuki K., Watanabe T., Mori H., Shirasawa T. (1998) J. Neurosci. 18, 2063–2074 [PubMed]
48. Chavous D. A., Jackson F. R., O'Connor C. M. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 14814–14818 [PubMed]
49. Zhu J. X., Doyle H. A., Mamula M. J., Aswad D. W. (2006) J. Biol. Chem. 281, 33802–33813 [PubMed]
50. Bidinosti M., Ran I., Sanchez-Carbente M. R., Martineau Y., Gingras A. C., Gkogkas C., Raught B., Bramham C. R., Sossin W. S., Costa-Mattioli M., DesGroseillers L., Lacaille J. C., Sonenberg N. (2010) Mol. Cell 37, 797–808 [PMC free article] [PubMed]
51. Reissner K. J., Paranandi M. V., Luc T. M., Doyle H. A., Mamula M. J., Lowenson J. D., Aswad D. W. (2006) J. Biol. Chem. 281, 8389–8398 [PubMed]
52. Böhme L., Bär J. W., Hoffmann T., Manhart S., Ludwig H. H., Rosche F., Demuth H. U. (2008) Biol. Chem. 389, 1043–1053 [PubMed]
53. Tarcsa E., Szymanska G., Lecker S., O'Connor C. M., Goldberg A. L. (2000) J. Biol. Chem. 275, 20295–20301 [PubMed]
54. Shimizu T., Fukuda H., Murayama S., Izumiyama N., Shirasawa T. (2002) J. Neurosci. Res. 70, 451–461 [PubMed]
55. Shirasawa T., Endoh R., Zeng Y. X., Sakamoto K., Mori H. (1995) Neurosci. Lett. 188, 37–40 [PubMed]
56. Lowenson J. D., Kim E., Young S. G., Clarke S. (2001) J. Biol. Chem. 276, 20695–20702 [PubMed]
57. Johnson B. A., Aswad D. W. (1990) Biochemistry 29, 4373–4380 [PubMed]
58. Haley E. E., Corcoran B. J., Dorer F. E., Buchanan D. L. (1966) Biochemistry 5, 3229–3235 [PubMed]
59. Banko J. L., Hou L., Poulin F., Sonenberg N., Klann E. (2006) J. Neurosci. 26, 2167–2173 [PubMed]
60. Banko J. L., Merhav M., Stern E., Sonenberg N., Rosenblum K., Klann E. (2007) Neurobiol. Learn. Mem. 87, 248–256 [PubMed]
61. Banko J. L., Poulin F., Hou L., DeMaria C. T., Sonenberg N., Klann E. (2005) J. Neurosci. 25, 9581–9590 [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology